Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy

BACKGROUND: Trastuzumab shows excellent benefits for HER2+ breast cancer patients, although 20% treated remain unresponsive. We conducted a retrospective cohort study to optimize neoadjuvant chemotherapy and trastuzumab treatment in HER2+ breast cancer patients. METHODS: Six hundred patients were an...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lun, Chen, Min, Zheng, Shuyue, Li, Hanlu, Chi, Weiru, Xiu, Bingqiu, Zhang, Qi, Hou, Jianjing, Wang, Jia, Wu, Jiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319743/
https://www.ncbi.nlm.nih.gov/pubmed/34336634
http://dx.doi.org/10.3389/fonc.2021.592393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319743/
https://www.ncbi.nlm.nih.gov/pubmed/34336634
http://dx.doi.org/10.3389/fonc.2021.592393

Ejemplares similares